SUSTAINABILITY

Environmental Sustainability

Cannacea is dedicated to preserving our miracle biosphere:

  • Certified Organic cultivation and production – Harmonious for your patients’ health and our Earth.
  • FSC Certified product boxes from responsibly-managed forests and recycled paper – Printed with vegetable inks.
  • Compostable bioplastic easy-peel bottle labels – Printed with compostable inks.
  • Recyclable dropper bottle glass, plastic caps and rubber bulbs.
  • Recycled 100% PCW paper and board for all shipping packaging and filler materials.

CANNABINOID SCIENCE

POTENCIES

PURITY

MACADAMIA NUT OIL

PRACTITIONER SUPPORT

REALM OF CARING FOUNDATION

References
  1. Aizpurua-Olaizola, O et al. (2017). Targeting the endocannabinoid system: future therapeutic strategies. Drug Discovery Today 22(1): 105-110.
  2. Morales, P, Reggio, PH (2017). An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors. Cannabis and Cannabinoid Research 2(1): 265-273.
  3. Stasiulewicz, A et al. (2020). A Guide to Targeting the Endocannabinoid System in Drug Design. International Journal of Molecular Sciences 21(8): 2778.
  4. VanDolah, HJ et al. (2019). Clinician’s Guide to Cannabidiol and Hemp Oils. Mayo Clinic Proceedings 94(9): 1840-1851.
  5. Sholler, DJ et al. (2020). Therapeutic Efficacy of Cannabidiol (CBD): A Review of the Evidence from Clinical Trials and Human Laboratory Studies. Current Addiction Reports 7(3): 405-412.
  6. Khan, R et al. (2020). The therapeutic role of Cannabidiol in mental health: a systematic review. Journal of Cannabis Research 2:2.
  7. Abuhasira, R et al. (2018). Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly. European Journal of Internal Medicine 49: 44-50.
  8. National Academies of Sciences, Engineering, and Medicine (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press.
  9. Russo, EB, Marcu, J (2017). Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads. Advances in Pharmacology 80: 67-134.
  10. Orsavova, J et al. (2015). Fatty Acids Composition of Vegetable Oils and Its Contribution to Dietary Energy Intake and Dependence of Cardiovascular Mortality on Dietary Intake of Fatty Acids. International Journal of Molecular Sciences 16(6): 12871-12890.
  11. Krut, LH, Bronte-Stewart, B (1964). The fatty acids of human depot fat. Journal of Lipid Research 5(3): 343-351.
  12. Turner, SE et al. (2017). Molecular Pharmacology of Phytocannabinoids. In Kinghorn, AD; Falk, H; Gibbons, S; Kobayashi, J (eds.). Phytocannabinoids: Unraveling the Complex Chemistry and Pharmacology of Cannabis sativa. Progress in the Chemistry of Organic Natural Products 103. Springer International Publishing: 61–101.
  13. De Petrocellis, L et al. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology 163(7): 1479-1494.
  14. Capano, A et al. (2020). Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgraduate Medicine 132(1): 56-61.
  15. Casarett, DJ et al. (2019). Benefit of Tetrahydrocannabinol versus Cannabidiol for Common Palliative Care Symptoms. Journal of Palliative Medicine 22(10): 1180-1184.
  16. Wagner, H, Ulrich-Merzenich, G (2009). Synergy research: Approaching a new generation of phytopharmaceuticals. Phytomedicine 16(2-3): 97-110.
  17. Rasoanaivo, P et al. (2011). Whole plant extracts versus single compounds for the treatment of malaria: synergy and positive interactions. Malaria Journal 10(Suppl.1): 1-12.
  18. Yuan, H et al. (2017). How Can Synergism of Traditional Medicines Benefit from Network Pharmacology? Molecules 22(7): 1135-1153.
  19. McPartland, JM, Russo, EB (2001). Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts? Journal of Cannabis Therapeutics 1(3-4): 103-132.
  20. Russo, E (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology 163(7): 1344-1364.
  21. Pamplona, FA et al. (2018). Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. Frontiers in Neurology 9: 759.
  22. Zafar, R et al. (2021). Medical cannabis for severe treatment resistant epilepsy in children: a case-series of 10 patients. BMJ Paediatrics Open 5: e001234.
  23. Gallily, R et al. (2015). Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol. Pharmacology and Pharmacy 6: 75-78.
  24. Lewis, MA et al. (2018). Pharmacological Foundations of Cannabis Chemovars. Planta Medica 84(04): 225-233.
  25. Karniol, IG et al. (1974). Cannabidiol interferes with the effects of delta 9- tetrahydrocannabinol in man. European Journal of Pharmacology 28(1): 172– 177.
  26. Zuardi, AW et al. (1982). Action of cannabidiol on the anxiety and other effects produced by δ9-THC in normal subjects. Psychopharmacology (Berl) 76(3): 245–250.
  27. Bhattacharyya, S et al. (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35(3): 764-774.
  28. Izzo, L et al. (2020). Analysis of Phenolic Compounds in Commercial Cannabis sativa L. Inflorescences Using UHPLC-Q-Orbitrap HRMS. Molecules 25(3): 631.

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.